Advanced management tactics for high-risk pregnant women with moderate novel coronavirus infection COVID-19

Aim: to assess efficacy and safety of using colloidal silicon dioxide as an adjunct therapy in managing high-risk pregnant women with moderate COVID-19.

Materials and Methods. A prospective comparative study was conducted by enrolling 62 pregnant women hospitalized with moderate COVID-19. Metabolic charts and delivery records were subsequently reviewed. Participants were divided into two groups: Group 1 (n = 32) received standard treatment, while Group 2 (n = 30) received standard treatment plus colloidal silicon dioxide. Clinical and laboratory markers of endotoxemia, pregnancy progression, and outcomes were assessed.

Results. It was found that in Group 2 vs. Group 1 mean length of the following symptoms was significantly shorter: hyperthermia – by 2.4 days (p = 0.011), tachycardia – by 2.2 days (p = 0.037), weakness – by 2.1 days (p = 0.137), and headache – by 1.7 days (p = 0.042). In addition, women from Group 2 also showed significantly lower C-reactive protein and interleukin-6 levels (p = 0.006 and p = 0.019, respectively) as well as lacked blood flow disturbances at significantly more frequent level primarily Grade 1B uteroplacental insufficiency. Grade III blood flow disturbances were observed in one patient in Group 1 but none in Group 2. Regarding delivery outcomes, 97 % of Group 1 pregnancies resulted in live births (mean body length – 49.25 ± 1.75 cm, mean birth weight – 3126 ± 245.6 g), with vacuum extraction observed in 9 % of cases and cesarean section – in 31 %. One case of antepartum fetal demise occurred. In Group 2, all pregnancies resulted in live births (mean body length – 51.5 ± 2.5 cm, mean birth weight – 3360 ± 260 g), with vacuum extraction in 3 % of cases and cesarean section – in 30 %. While some patients exhibited combinations of these parameters, no significant inter-group differences were found. Assessing neonatal condition at one minute postpartum revealed significantly more cases of mild asphyxia in Group 1; the number of newborns without asphyxia was twice as high in Group 2 (p = 0.021).

Conclusion. Comparing course of pregnancy, delivery, neonatal condition, and management of high-risk pregnant women with moderate COVID-19 using the proposed methodology suggests its high efficacy and safety.

1. Adamyan L.V., Konysheva O.V., Lyashko E.S. et al. Features of obstetric care in the context of coronavirus infection. Diagnosis and treatment of novel coronavirus infection. Organization of work in a multidisciplinary hospital: a guide for doctors. Ed. V.I. Vechorko. [Osobennosti rodovspomozheniya v usloviyah koronavirusnoj infekcii. Diagnostika i lechenie novoj koronavirusnoj infekcii. Organizaciya raboty v usloviyah mnogoprofil'nogo stacionara: rukovodstvo dlya vrachej. Pod red. V.I. Vechorko]. Moscow: Praktika, 2020. 242–53. (In Russ.). https://doi.org/10.51833/9785898161804_242.

2. Saadaoui M., Kumar M., Al Khodor S. COVID-19 Infection during pregnancy: risk of vertical transmission, fetal, and neonatal outcomes. J Pers Med. 2021;11(6):483. https://doi.org/10.3390/jpm11060483.

3. Organization of medical care for pregnant women, women in labor, women in labor and newborns with novel coronavirus infection COVID-19: guidelines. Version 4 (05.07.2021). [Organizaciya okazaniya medicinskoj pomoshchi beremennym, rozhenicam, rodil'nicam i novorozhdennym pri novoj koronavirusnoj infekcii COVID-19: metodicheskie rekomendacii. Versiya 4 (05.07.2021)]. Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2021. 131 p. (In Russ.). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/057/311/original/05072021_MR_Preg_v4.pdf?1625512556. [Accessed: 21.09.2024].

4. Di Mascio D., Khalil A., Saccone G. et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;2(2):100107. https://doi.org/10.1016/j.ajogmf.2020.100107.

5. Menshikova S.V., Ketova G.G., Popilov M.A. Under-reported properties of polisorb mp (colloidal silica). [Maloizvestnye svojstva polisorba MP (dioksida kremniya kolloidnogo)]. Glavnyj vrach Yuga Rossii. 2018;(1):32–4. (In Russ.).

6. Belotserkovtseva L.D., Kovalenko L.V., Telitsyn D.P. Molecular genetic predictors of early pre-eclampsia. [Molekulyarno-geneticheskie prediktory rannej preeklampsii]. Vestnik SurGU. Medicina. 2017;(3):6–12. (In Russ.).

7. Belotserkovtseva L.D., Telitsyn D.P., Kovalenko L.V. et al. Genetic predictors of early and late forms of pre-eclampsia. Pathogenetic approaches to treatment of pre-eclampsia. [Geneticheskie prediktory rannej i pozdnej form preeklampsii. Patogeneticheskie podhody k lecheniyu preeklampsii]. Vestnik SurGU. Medicina. 2019;(4):79–86. (In Russ.).

8. Yulish E.I., Krivuschev B.I. Enterosorption for toxic syndrome treatment. [Metod enterosorbcii v lechenii sindroma intoksikacii]. Zdorov'e rebenka. 2011;(4):76–81. (In Russ.).

9. Tikhonova E.P., Savchenko A.A., Kuzmina T.Yu. et al. The use of enterosorbents in the immunorehabilitation of patients who have recovered from the new coronavirus infection COVID-19. [Primenenie enterosorbentov v immunoreabilitacii bol'nyh, perebolevshih novoj koronavirusnoj infekciej COVID-19]. Infekcionnye bolezni: novosti, mneniya, obuchenie. 2021;10(4):29–37. (In Russ.). https://doi.org/10.33029/2305-3496-2021-10-4-29-37.

10. Romanovskaya A.V., Mikhailova E.V., Denisyuk N.E., Tyapkina D.A. Efficacy of enterosorption in treatment of Covid-19 in pregnant women. [Effektivnost' enterosorbcii pri lechenii COVID-19 u beremennyh]. Permskij medicinskij zhurnal. 2022;39(6):54–61. (In Russ.). https://doi.org/10.17816/pmj39654-61.